

# CITATION REPORT

List of articles citing

## Molecular landscape of pancreatic cancer: implications for current clinical trials

DOI: 10.18632/oncotarget.2972  
Oncotarget, 2015, 6, 4553-61.

**Source:** <https://exaly.com/paper-pdf/87796532/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
79	The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4561-8	12.9	17
78	Morphological and immunohistochemical profile of pancreatic neuroendocrine neoplasms. <i>Polish Journal of Pathology</i> , <b>2015</b> , 66, 176-94	0.9	5
77	Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges. <i>Seminars in Oncology</i> , <b>2015</b> , 42, 549-61	5.5	33
76	PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. <i>Oncogenesis</i> , <b>2015</b> , 4, e169	6.6	35
75	Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. <i>Oncotarget</i> , <b>2016</b> , 7, 5943-56	3.3	46
74	Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature. <i>Oncotarget</i> , <b>2016</b> , 7, 62533-62546	3.3	33
73	Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection. <i>Oncotarget</i> , <b>2016</b> , 7, 54526-54536	3.3	59
72	Impact of 3'TUTR variation patterns of the KRAS gene on the aggressiveness of pancreatobiliary tumors with the KRAS G13D mutation in a Turkish population. <i>Pancreatology</i> , <b>2016</b> , 16, 677-86	3.8	1
71	K-Ras4B/calmodulin/PI3K/A promising new adenocarcinoma-specific drug target?. <i>Expert Opinion on Therapeutic Targets</i> , <b>2016</b> , 20, 831-42	6.4	29
70	Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. <i>European Journal of Cancer</i> , <b>2016</b> , 54, 75-83	7.5	107
69	The emerging roles of F-box proteins in pancreatic tumorigenesis. <i>Seminars in Cancer Biology</i> , <b>2016</b> , 36, 88-94	12.7	15
68	Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. <i>Journal of Clinical Pathology</i> , <b>2016</b> , 69, 403-8	3.9	40
67	Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 76-87	6.1	49
66	Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. <i>International Journal of Cancer</i> , <b>2017</b> , 140, 2344-2350	7.5	88
65	Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A. <i>Cellular Physiology and Biochemistry</i> , <b>2017</b> , 43, 2420-2433	3.9	66
64	Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis. <i>Molecular Medicine Reports</i> , <b>2017</b> , 16, 4784-4790	2.9	9
63	Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 2645-2655	6.1	39

62	Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. <i>Biomedicines</i> , <b>2017</b> , 5,	4.8	49
61	Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185687	3.7	12
60	Genetics of pancreatic cancer and implications for therapy. <i>Abdominal Radiology</i> , <b>2018</b> , 43, 404-414	3	7
59	Micro-Inversions In Human Cancer Genomes. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference</i> , <b>2018</b> , 2018, 1323-1326	0.9	1
58	A potential novel therapy for FGFR1-amplified pancreatic cancer with bone metastasis, screened by next-generation sequencing and a patient-derived xenograft model. <i>Oncology Letters</i> , <b>2019</b> , 17, 2303-2307	2.6	7
57	The Use of Biomarkers in the Risk Stratification of Cystic Neoplasms. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>2018</b> , 28, 549-568	3.3	8
56	The Cell Cycle. <b>2018</b> , 197-219		7
55	Clinical update on K-Ras targeted therapy in gastrointestinal cancers. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 130, 78-91	7	11
54	Expression of miRNA-143 in Pancreatic Cancer and Its Clinical Significance. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2018</b> , 33, 373-379	3.9	17
53	Increased KIF4A expression is a potential prognostic factor in prostate cancer. <i>Oncology Letters</i> , <b>2018</b> , 15, 7941-7947	2.6	19
52	New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	17
51	Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. <i>Diagnostic Pathology</i> , <b>2019</b> , 14, 62	3	4
50	Antitumor activity of potent pyruvate dehydrogenase kinase 4 inhibitors from plants in pancreatic cancer. <i>Molecular Carcinogenesis</i> , <b>2019</b> , 58, 1726-1737	5	8
49	miR-223 Regulates Cell Proliferation and Invasion via Targeting PDS5B in Pancreatic Cancer Cells. <i>Molecular Therapy - Nucleic Acids</i> , <b>2019</b> , 14, 583-592	10.7	16
48	Evolving trends in pancreatic cancer therapeutic development. <i>Annals of Pancreatic Cancer</i> , <b>2019</b> , 2,	1.3	
47	Targeting the epigenome as a therapeutic strategy for pancreatic tumors: noncoding RNAs and chromatin remodelers. <b>2019</b> , 211-244		
46	Long non-coding RNA MCM3AP-AS1 promotes growth and migration through modulating FOXK1 by sponging miR-138-5p in pancreatic cancer. <i>Molecular Medicine</i> , <b>2019</b> , 25, 55	6.2	24
45	Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. <i>Journal of Hematology and Oncology</i> , <b>2019</b> , 12, 130	22.4	35

44	Establishment and Characterization of 10 Human Pancreatic Cancer Cell Lines Including a HER2 Overexpressed Cell Line. <i>Pancreas</i> , <b>2019</b> , 48, 1285-1293	2.6	3
43	Comparison of endoscopic ultrasound tissue acquisition methods for genomic analysis of pancreatic cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 907-913	4	22
42	Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2185-2193	12.9	22
41	Small molecule tyrosine kinase inhibitors and pancreatic cancer-Trials and troubles. <i>Seminars in Cancer Biology</i> , <b>2019</b> , 56, 149-167	12.7	13
40	Germline genetic variability in pancreatic cancer risk and prognosis. <i>Seminars in Cancer Biology</i> , <b>2020</b> , 79, 105-105	12.7	11
39	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1491-1505	10.3	223
38	Synthesis of propargylamines via the A multicomponent reaction and their biological evaluation as potential anticancer agents. <i>Organic and Biomolecular Chemistry</i> , <b>2020</b> , 18, 2475-2486	3.9	6
37	Next-Generation Sequencing in Cytopathology. <i>Monographs in Clinical Cytology</i> , <b>2020</b> , 34-42	0.2	2
36	Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic Adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , <b>2021</b> , 52, 160-168	1.6	0
35	Side-by-side comparison of next-generation sequencing, cytology, and histology in diagnosing locally advanced pancreatic adenocarcinoma. <i>Gastrointestinal Endoscopy</i> , <b>2021</b> , 93, 597-604.e5	5.2	9
34	Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 40992-41004	3.3	56
33	Hereditary Syndromes and Pancreatic Cancer. <b>2021</b> , 29-49		
32	Long non-coding RNA PCED1B-AS1 promotes pancreatic ductal adenocarcinoma progression by regulating the miR-411-3p/HIF-1 $\alpha$ axis. <i>Oncology Reports</i> , <b>2021</b> , 46,	3.5	5
31	Targeting DNA damage repair pathways in pancreas cancer. <i>Cancer and Metastasis Reviews</i> , <b>2021</b> , 40, 891-908	9.6	6
30	SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	4
29	Remarkable response of -mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report.. <i>Gastroenterology Report</i> , <b>2022</b> , 10, goab031	3.3	
28	Long Non-Coding RNA Differentiation Antagonizing Nonprotein Coding RNA (DANCR) Promotes Proliferation and Invasion of Pancreatic Cancer by Sponging miR-214-5p to Regulate E2F2 Expression. <i>Medical Science Monitor</i> , <b>2019</b> , 25, 4544-4552	3.2	20
27	Usefulness of rapid on-site evaluation specimens from endoscopic ultrasound-guided fine-needle aspiration for cancer gene panel testing: A retrospective study. <i>PLoS ONE</i> , <b>2020</b> , 15, e0228565	3.7	2

26	Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 72819-72832	3.3	11
25	The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 4183-94	3.3	65
24	The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 20293-304	3.3	20
23	Periostin promotes tumor angiogenesis in pancreatic cancer via Erk/VEGF signaling. <i>Oncotarget</i> , <b>2016</b> , 7, 40148-40159	3.3	29
22	Evaluation and diagnostic value of next-generation sequencing analysis of residual liquid-based cytology specimens of pancreatic masses. <i>Cancer Cytopathology</i> , <b>2021</b> ,	3.9	1
21	MA-mediated up-regulation of LncRNA LIFR-AS1 enhances the progression of pancreatic cancer via miRNA-150-5p/ VEGFA/Akt signaling. <i>Cell Cycle</i> , <b>2021</b> , 20, 2507-2518	4.7	7
20	Pancreatic Ductal Adenocarcinoma. <b>2016</b> , 8-108-8-111		
19	Tyrosine Kinase Inhibitors and Their Clinical Prospective in Pancreatic Cancer. <b>2018</b> , 63-70		
18	Role of FHL2 in digestive system malignancies. <i>World Chinese Journal of Digestology</i> , <b>2019</b> , 27, 1083-1087.1		
17	Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , <b>2016</b> , 7, E6-E12	2.8	1
16	Rottlerin exhibits anti-cancer effect through inactivation of S phase kinase-associated protein 2 in pancreatic cancer cells. <i>American Journal of Cancer Research</i> , <b>2016</b> , 6, 2178-2191	4.4	20
15	Pancreatic Cancer, A Mis-interpreter of the Epigenetic Language. <i>Yale Journal of Biology and Medicine</i> , <b>2016</b> , 89, 575-590	2.4	9
14	The lncRNA-HOXA-AS2/EZH2/LSD1 oncogene complex promotes cell proliferation in pancreatic cancer. <i>American Journal of Translational Research (discontinued)</i> , <b>2017</b> , 9, 5496-5506	3	35
13	MicroRNA-204 attenuates the migration and invasion of pancreatic cancer cells by targeting ZEB1/EMT axis. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2018</b> , 11, 3802-3811	1.4	1
12	The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets.. <i>Biomolecules</i> , <b>2022</b> , 12,	5.9	3
11	Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next-generation sequencing acquired by endoscopic ultrasound-guided FNA and FNB.. <i>Cancer Cytopathology</i> , <b>2021</b> ,	3.9	0
10	Insulin receptors in pancreatic acinar cells contribute to KrasG12D-driven cancer initiation in the context of diet-induced obesity.		
9	Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2022</b> , 103749	7	1

8	Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival. <i>Oncotarget</i> , <b>2022</b> , 13, 828-841	3.3	0
7	Combined Systemic Drug Treatment with Proton Therapy: Investigations on Patient-Derived Organoids. <b>2022</b> , 14, 3781		1
6	Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and Efficacy. <b>2022</b> , 14, 5436		1
5	Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening. <b>2022</b> , 29, 8693-8719		1
4	Inhibitor of DNA binding/differentiation proteins as IDs for pancreatic cancer: Role in pancreatic cancer initiation, development and prognosis. <b>2023</b> , 853, 147092		0
3	Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. <b>2023</b> , 8,		1
2	Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden. 13,		0
1	Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment.		0